Biotech Values

[DewDiligence]

Addendum re R. Karnauskas – Regado/MNTA:

Peter et al: Perhaps the most interesting thing Robyn said in either the MNTA CC or the written report is that she considers Regado’s RB006 the most direct competitor to M118. Info on RB006 can be found in #msg-32171800.

Other than the fact that RB006 and M118 are both novel and reversible, I don’t think they are much alike. Regards, Dew

p.s. I wonder if Robyn knows about the TB-402 program (#msg-39349539).